{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:24:27Z","timestamp":1740108267330,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T00:00:00Z","timestamp":1447200000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00198-015-3402-9","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T16:53:22Z","timestamp":1447260802000},"page":"1653-1658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of off-label use of denosumab 60\u00a0mg injection during the early postmarketing period using health insurance claims data"],"prefix":"10.1007","volume":"27","author":[{"given":"V.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Gardstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Skerry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. W.","family":"Critchlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Enger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,11]]},"reference":[{"issue":"5","key":"3402_CR1","first-page":"362","volume":"14","author":"MS Lipsy","year":"2001","unstructured":"Lipsy MS, Sharp LK (2001) From idea to market: the drug approval process. J Am Board Fam Pract 14(5):362\u2013367","journal-title":"J Am Board Fam Pract"},{"issue":"9","key":"3402_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","volume":"166","author":"DC Radley","year":"2006","unstructured":"Radley DC, Finkelstein SN, Stafford RS (2006) Off-label prescribing among office-based physicians. Arch Intern Med 166(9):1021\u20131026. doi: 10.1001\/archinte.166.9.1021","journal-title":"Arch Intern Med"},{"issue":"12","key":"3402_CR3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/pds.1668","volume":"17","author":"R Platt","year":"2008","unstructured":"Platt R, Madre L, Reynolds R et al (2008) Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 17(12):1175\u201382","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"3402_CR4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/pds.3312","volume":"21","author":"AS Czaja","year":"2012","unstructured":"Czaja AS, Valuck R (2012) Off\u2010label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. Pharmacoepidemiol Drug Saf 21(9):997\u20131004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"3402_CR5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.18553\/jmcp.2007.13.5.420","volume":"13","author":"PP Gleason","year":"2007","unstructured":"Gleason PP, Walters C, Heaton AH et al (2007) Telithromycin: the perils of hasty adoption and persistence of off\u2010label prescribing. J Manag Care Pharm 13(5):420\u2013425","journal-title":"J Manag Care Pharm"},{"key":"3402_CR6","unstructured":"(2012) Prolia\u00ae (denosumab) prescribing information, Amgen. Revised September."},{"issue":"8","key":"3402_CR7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821\u2013831","journal-title":"N Engl J Med"},{"issue":"30","key":"3402_CR8","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chiebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875\u20134882","journal-title":"J Clin Oncol"},{"key":"3402_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4137\/CMO.S8511","volume":"6","author":"A Lipton","year":"2012","unstructured":"Lipton A, Smith MR, Ellis GK, Goessl C (2012) Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol 6:287\u2013303. doi: 10.4137\/CMO.S8511","journal-title":"Clin Med Insights Oncol"},{"issue":"8","key":"3402_CR10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"11","key":"3402_CR11","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, Chapurlat R, Brandi ML et al (2013) The effect of 3 or 6\u00a0years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98(11):4483\u20134492. doi: 10.1210\/jc.2013-1597","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3402_CR12","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, Czerwinski E, Bone HG et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121(6):1291\u20131299. doi: 10.1097\/AOG.0b013e318291718c","journal-title":"Obstet Gynecol"},{"issue":"9","key":"3402_CR13","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbj\u00e6rg CS, Langdahl BL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97(9):3161\u20139. doi: 10.1210\/jc.2012-1569","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3402_CR14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1445-5994.2008.01732.x","volume":"39","author":"E Romas","year":"2009","unstructured":"Romas E (2009) Clinical applications of RANK\u2010ligand inhibition. Intern Med J 39(2):110\u2013116","journal-title":"Intern Med J"},{"issue":"10","key":"3402_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrrheum.2009.175","volume":"5","author":"Y Choi","year":"2009","unstructured":"Choi Y, Arron JR, Townsend MJ (2009) Promising bone-related targets for rheumatoid arthritis therapy. Nat Rev Rheumatol 5(10):543\u2013548. doi: 10.1038\/nrrheum.2009.175","journal-title":"Nat Rev Rheumatol"},{"key":"3402_CR16","unstructured":"XGEVA\u00ae (denosumab) prescribing information, Amgen. Revised January 2013"},{"issue":"9","key":"3402_CR17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/pds.3680","volume":"23","author":"V Hoffman","year":"2014","unstructured":"Hoffman V, Xue F, Gardstein B et al (2014) Development and evaluation of an algorithm to identify users of Prolia\u00ae during the early postmarketing period using health insurance claims data. Pharmacoepidemiol Drug Saf 23(9):993\u2013998. doi: 10.1002\/pds.3680","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3402_CR18","volume-title":"Clinician's guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"2010","unstructured":"National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC"},{"issue":"10","key":"3402_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/pds.3477","volume":"22","author":"F Xue","year":"2013","unstructured":"Xue F, Ma H, Stehman-Breen C et al (2013) For the denosumab global safety assessment team. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia\u00ae(denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf 22(10):1107\u201314. doi: 10.1002\/pds.3477","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3402-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3402-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3402-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3402-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T07:38:19Z","timestamp":1599809899000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3402-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,11]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["3402"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3402-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2015,11,11]]}}}